---
title: "Xbrane Sets April–May Target to Resubmit Ranibizumab Biosimilar BLA to U.S. FDA"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281254166.md"
description: "Xbrane Sets April–May Target to Resubmit Ranibizumab Biosimilar BLA to U.S. FDA"
datetime: "2026-03-31T21:49:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281254166.md)
  - [en](https://longbridge.com/en/news/281254166.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281254166.md)
---

# Xbrane Sets April–May Target to Resubmit Ranibizumab Biosimilar BLA to U.S. FDA

Xbrane Sets April–May Target to Resubmit Ranibizumab Biosimilar BLA to U.S. FDA

### Related Stocks

- [XBIO.US](https://longbridge.com/en/quote/XBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [AMAM.US](https://longbridge.com/en/quote/AMAM.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ZBIO.US](https://longbridge.com/en/quote/ZBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [Immix Biopharma Announces 95% Complete Response Rate In Interim Update From Relapsed/Refractory AL Amyloidosis Clinical Trial NEXICART-2](https://longbridge.com/en/news/287200923.md)
- [Zenas BioPharma To Present INDIGO Phase 3 Data At EULAR 2026; Wedbush Sees $45 Target](https://longbridge.com/en/news/286916856.md)
- [Zentalis to Present Phase 1b MUIR Data: 39% ORR, 7.3‑month PFS; 50% ORR at 250 mg Cohort](https://longbridge.com/en/news/287276070.md)
- [Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition](https://longbridge.com/en/news/286608288.md)
- [Zenas BioPharma Insider Bought Shares Worth $1,012,800, According to a Recent SEC Filing](https://longbridge.com/en/news/286872009.md)